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Abstract Memapsin 2, or L-secretase, is a membrane-anchored
aspartic protease that initiates the cleavage of L-amyloid pre-
cursor protein (APP) leading to the production of L-amyloid
peptide in the brain and the onset of Alzheimer’s disease. Mem-
apsin 2 and APP are both endocytosed into endosomes for
cleavage. Here we show that the cytosolic domain of memapsin
2, but not that of memapsin 1, binds the VHS domains of
GGA1 and GGA2. Gel-immobilized VHS domains of GGA1
and GGA2 also bound to full-length memapsin 2 from cell
mammalian lysates. Mutagenesis studies established that
Asp496, Leu499 and Leu500 were essential for the binding. The
spacing of these three residues in memapsin 2 is identical to
those in the cytosolic domains of mannose-6-phosphate recep-
tors, sortilin and low density lipoprotein receptor-related protein
3. These observations suggest that the endocytosis and intra-
cellular transport of memapsin 2, mediated by its cytosolic do-
main, may involve the binding of GGA1 and GGA2. . 2002
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Memapsin 2 [1], also called BACE [2] or ASP-2 [3,4], is a
membrane-associated aspartic protease that has long been
known as L-secretase. Memapsin 2 hydrolyzes a membrane
protein, L-amyloid precursor protein (APP), and together
with another protease, Q-secretase, release a 40/42 residue frag-
ment called L-amyloid (AL). Since the accumulation of AL in
the brain is a central event leading to Alzheimer’s disease (see
[5] for a recent review), memapsin 2 is generally regarded as a
major therapeutic target for the development of inhibitor
drugs. For a better understanding of this target, there is a
great deal of current interest in the intracellular activities of
memapsin 2.
The newly synthesized pro-memapsin 2 is known to be pro-
cessed in the secretory pathway by furin [6^8] and transported
to the cell surface where APP is also present [9]. Both APP
and memapsin 2 are endocytosed into the early endosomes
where APP is cleaved by memapsin 2 at the L-secretase site.
Although APP cleavage by L-secretase has been reported also
for endoplasmic reticulum and Golgi, endosomes are likely
the major site for L-secretase processing owing to an acidic
pH activity of the enzyme [1^4]. Endosomal memapsin 2 has
been shown to recycle back to the cell surface [9], possibly via
the trans-Golgi network although this has not been demon-
strated. The endocytosis of membrane proteins is in general
mediated by their cytosolic domains (see [10,11] for review).
For memapsin 2, two leucine residues at positions 499 and
500 (Table 1) in its cytosolic domain have been shown to be
essential for its endocytosis [9,12].
Recently, the involvement of a family of GGA (Golgi-lo-
calized Q-ear-containing ARF binding) proteins in the regula-
tion of intracellular transport of membrane proteins has be-
come clear (see [13] for a recent review). The N-terminal VHS
(Vps-27, Hrs and STAM) domains of GGA proteins were
shown to bind the cytosolic domain of cation-independent
and cation-dependent mannose-6-phosphate receptors (CI-
MPR and CD-MPR respectively) [14^16], sortilin [16,17]
and the low density lipoprotein receptor-related protein 3
[17]. This binding is believed to be the ¢rst step in the recruit-
ment of these membrane proteins to the Golgi membrane for
packaging into the vesicles targeting to endosomes [14^17].
Although memapsin 2 has not been shown to be transported
from trans-Golgi to endosomes, we however found sequence
similarity of its C-terminal region to that of GGA binding
proteins mentioned above (Table 1, A). Here we report that
the C-terminal region of the cytosolic domain of memapsin 2
binds to human GGA1 and GGA2.
2. Materials and methods
2.1. cDNA cloning and protein expression
cDNAs of human GGA1 and GGA2 [18] were kindly provided by
Dr. M.S. Robinson, University of Cambridge. For the construct of
glutathione S-transferase (GST)^VHS fusion proteins, the cDNAs
encoding the VHS domain from GGA1 (corresponding to residues
1^147) and GGA2 (residues 13^72) were separately ampli¢ed by
PCR and cloned into plasmid pGEX2T (Amersham-Pharmacia, Pis-
cataway, NJ, USA) and expressed in Escherichia coli strain BL21.
Three hours after the induction with isopropyl-L-D-thiogalactoside,
the bacterial cells were collected and lysed by sonication. The fusion
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proteins in the supernatant of the lysate were puri¢ed by a⁄nity
chromatography using a glutathione-Sepharose 4B column.
2.2. Peptides
The nomenclature and sequences of the peptides used are shown in
Table 1. These peptide sequences were derived from the C-terminal
regions of the cytosolic domains of the proteins. A cysteine was added
to the N-terminus of peptide CI-MPR for gel attachment. All peptides
were synthesized at Research Genetics (Huntsville, AL, USA) except
CI-MPR, which was synthesized at Synpep (Dublin, CA, USA).
2.3. Binding experiments
The peptides were covalently linked by their thiol groups to Sulfo-
link Coupling Gel (Pierce) using the procedure provided by the man-
ufacturer. Gel bearing immobilized peptide (150 Wl) and individual
GST^VHS proteins (200 Wg) were incubated in 1.5 ml phosphate-bu¡-
ered saline (PBS) at room temperature for 2 h. The gel beads were
pelleted by centrifugation at 750Ug for 1 min and washed three times
with PBS. The proteins on the gel beads were eluted by sodium do-
decylsulfate (SDS)-containing sample bu¡er and subjected to SDS^
PAGE electrophoresis.
2.4. Pull-down experiments
The constructs of expression vectors of human memapsin 2 and
Swedish mutant of APP cDNAs and their transfection into HEK
293 cells will be described elsewhere. Transfected cells were main-
tained in Dulbecco’s modi¢ed Eagle’s medium containing 10% fetal
bovine serum, 100 U/ml penicillin, 100 Wg/ml streptomycin (Gibco
BRL), 250 Wg/ml Geneticin (G418 from Gibco BRL) and 5 Wg/ml
zeocin (Invitrogen). Cells were collected and lysed on ice in bu¡er
A (50 mM Tris^HCl, pH 7.4, containing 300 mM NaCl and 1%
Nonidet P-40). A mixture of 100 Wl of centrifuged supernatant of
the lysate, 900 Wl of bu¡er A and 100 Wg of GST^VHS fusion protein
was incubated overnight at 4‡C. An aliquot of 80 Wl of glutathione-
Sepharose (Pharmacia) suspension was added and the incubation con-
tinued for 6 h. The glutathione-Sepharose beads were then recovered
by centrifugation, washed three times with bu¡er A at 4‡C and re-
suspended in SDS-containing sample bu¡er for SDS^PAGE. The
presence of memapsin 2 in the electrophoresis was identi¢ed by West-
ern blot using rabbit polyclonal antibodies (Covance, Denver, PA,
USA) against recombinant pro-memapsin 2 [1]. The antibodies were
a⁄nity-puri¢ed using A⁄gel (Bio-Rad)-immobilized memapsin 2 pro-
tease domain [1].
3. Results
3.1. The cytosolic domain of memapsin 2, but not memapsin 1,
binds the VHS domains of GGA1 and GGA2
The binding of the VHS domains from GGA1 and GGA2
to peptides derived from the C-terminal regions of the cyto-
solic domains of memapsin 2 and memapsin 1 was studied. In
these experiments, VHS proteins bound to peptides immobi-
lized on gel beads were eluted and visualized on SDS^PAGE.
Fig. 1 shows that puri¢ed GST^VHS fusion proteins from
GGA1 and GGA2 appeared as single bands. A peptide
from the C-terminal region of CI-MPR was used as the pos-
itive control and cysteine-blocked gel as the negative control.
The peptide from memapsin 2 produced clear bands corre-
sponding to GST^VHS from both GGA1 (Fig. 1A) and
GGA2 (Fig. 1B). The peptide derived from memapsin 1, how-
ever, did not bind to either VHS domain. These observations
indicate that the cytosolic domain of memapsin 2, but not
that of memapsin 1, binds to GGA1 and GGA2.
3.2. Residue requirements of memapsin 2 cytosolic region for
VHS binding
The residues in the memapsin 2 C-terminal sequence re-
quired for binding to the VHS domains of GGA1 and
GGA2 were studied by selectively replacing them with ala-
nines (Table 1, B) and the binding of VHS proteins to the
peptides immobilized on gel was determined. First, a series of
modi¢ed M2 peptides was designed, each containing a substi-
tution of two alanines for an adjacent pair of residues, span-
Table 1
Sequence alignment for the C-terminal regions of proteins and peptide nomenclature
aThree conserved residues are shown in boldface.
bSubstituent alanine residues are shown in boldface.
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ning from Asp491 to Leu500 with exception for residue Ala494.
Fig. 2 shows binding of these peptides to the VHS domain of
GGA1 (panel A) and GGA2 (panel B). In both cases, the
replacement of either residues Asp495 and Asp496 or Leu499
and Leu500 abolished binding. The replacement of other resi-
dues, however, did not have an e¡ect. Peptides with single
residue replacement then established that, in both GGA1
(panel C) and GGA2 (panel D), the change of either
Asp496, Leu499 or Leu500 abolished the binding. The replace-
ment of Asp495 did not a¡ect the binding. These results
showed that Asp496, Leu499 and Leu500 are essential residues
for VHS/GGA binding.
3.3. Binding of VHS domains of GGA1 and GGA2 to
memapsin 2 from cell lysate
To show that the VHS domains of GGA1 and GGA2 can
bind to the full-length memapsin 2, we performed ‘pull-down’
experiments to test the binding of memapsin 2 in cell lysates
to gel-immobilized GST^VHS fusion proteins. Clear bands
corresponding to full-length memapsin 2 were present in
Western blot from the eluents of both VHS domains from
GGA1 and GGA2 (Fig. 3). Immobilized GST, as a negative
control, did not bind to memapsin 2 in the cell lysate. These
observations indicate that the VHS domains also bind the full-
length memapsin 2.
4. Discussion
We have demonstrated above that the C-terminal region of
memapsin 2 binds to the VHS domain of GGA1 and GGA2.
Similar binding of GGAs to the cytosolic domains of CI-
MPR, CD-MPR [14^16] and sortilin [16,17] have been shown
recently and such binding is considered to be a recognition
step in the targeting of these receptors for intracellular trans-
port. In this mechanism, the remaining GGA domains follow-
ing the VHS interact with adapter proteins, such as ARF-1,
and clathrin to package the VHS-bound membrane proteins
into transport vesicles for speci¢c destinations. The current
results, therefore, suggest that the GGA/VHS recognition of
the cytosolic domain of memapsin 2 is also a recognition step
that facilitates the intracellular transport of memapsin 2. It is
interesting to note, however, that the GGA involvement in
MPRs and sortilin is mainly for the transport of these mem-
brane receptors from trans-Golgi to endosomes (see [19,20] for
Fig. 1. Binding of VHS domain of GGA1 (A) and GGA2 (B) to peptide M2 (Table 1) from the C-terminal of human memapsin 2 (see Table
1, A). Peptides M2, M1 (from the C-terminal region of human memapsin 1) and CI-MPR (positive control) were immobilized on beaded aga-
rose gel. After binding of GST^VHS fusion proteins, the bound protein was determined by SDS^PAGE. Cysteine-blocked gel was used as neg-
ative control.
Fig. 2. Binding of alanine-substituted memapsin 2 C-terminal peptide (M2) to the VHS domains of GGA1 (A,C) and GGA2 (B,D). The se-
quences of the peptides are shown in Table 1, B. The binding experiments were carried out under similar conditions as those in Fig. 1.
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reviews). This is consistent with the observation that the high-
est concentration of GGAs in the cell is found in the trans-
Golgi membrane. Memapsin 2 has been shown to be endocy-
tosed into endosomes while its transport from trans-Golgi
directly to endosomes has not been demonstrated. In view
of the similarity in the GGA binding motifs for memapsin 2
and MPRs, the possibility exists that memapsin 2 may also be
transported from trans-Golgi to endosomes. The question if
GGAs are involved in the endocytosis of memapsin 2 is also
intriguing. Although VHS-containing proteins are known to
participate in the endocytosis mechanism (see [21] for review),
the involvement of GGAs in this process has not been shown.
However, MPRs are known to also be present on the cell
surface where they bind and transport the secreted lysosomal
enzymes to the endosomes. The cell surface MPRs may pos-
sibly utilize the same cytosolic pool of GGAs for its endocy-
tosis mechanism, which would be very similar to that for the
endocytosis of memapsin 2 and transport to endosomes.
The residues essential for the binding of memapsin 2 C-ter-
minal region to VHS are Asp496, Leu499 and Leu500. The same
three residues in identical relative positions are also found for
CI-MPR and CD-MPR binding to VHS domains [14,15] (see
Table 1 alignment). The crystal structures of the VHS do-
mains of GGA1 [22] and GGA3 [23] bound to peptides of
CI-MPR C-terminal region have been reported recently. Sub-
stitution of the CI-MPR peptide in the VHS of GGA1 struc-
ture with a C-terminal peptide of memapsin 2 by modeling
produced an excellent ¢t (results not shown). The interactions
of all three essential residues of the peptide with VHS residues
are retained. Although the memapsin 2 peptide is one residue
shorter at the C-terminus when aligned with the CI-MPR
peptide (Table 1), the C-terminal carboxyl group of Lys501
is free to interact with the side chain of Lys101 and Tyr102
of VHS and thus be stabilized. Ile497 of memapsin 2 is an
interesting residue in this structural comparison. The corre-
sponding residue in CI-MPR is a Glu located away from the
binding interface and having contact only with solvent mole-
cules but not with the VHS residues. Ile497 is a hydrophobic
residue that seems unsuited for such a position. However, the
side chain of Ile497 in the model of M2 complex with VHS [21]
is not within the distance for hydrophobic interaction with
any residue of the protein. Whether this surface isoleucine
residue is involved in other recognition functions remains to
be seen.
In contrast to memapsin 2, the cytosolic peptide of mem-
apsin 1 did not bind GGA1 or GGA2. Although memapsin 1
is the closest homologue of memapsin 2 (about 50% residue
identity) and also a class I membrane protein, the absence of
GGA binding is not unexpected in view that its C-terminal
region does not contain the essential dileucine/acidic cluster
motif (Table 1). These observations suggest that memapsin 1
may have a mechanism of recognition for intracellular trans-
port di¡erent from that of memapsin 2. Even though these
two proteases have very close speci¢cities [24] and are both
present in many cell types [1,2], the possible di¡erence in
transport destination may result in di¡erent cellular localiza-
tions and roles.
Since memapsin 2 performs the ¢rst cleavage in APP lead-
ing to the production of AL and the pathogenesis of Alzhei-
mer’s disease, it seems possible that the interaction of mem-
apsin 2 C-terminal region with GGAs can be a target for
drugs which disrupt this process and thus the production of
AL. However, there are serious questions concerning this drug
target. It is clear that GGAs interact with many membrane
proteins so selectivity for such disruption may indeed be very
challenging. Although the transport of memapsin 2 and APP
to endosomes has been shown to lead to the L-secretase cut
and AL production [9], the production of AL in the endoplas-
mic reticulum and Golgi has also been reported [25,26]. Such
reaction sites would not require the GGA-mediated memapsin
2 transport. However, as discussed in Section 1, endoplasmic
reticulum and Golgi do not have su⁄ciently high acidity to
support a signi¢cant memapsin 2 activity. At any rate, the
validity of this interaction as a drug target will need further
veri¢cation.
Acknowledgements: We thank Marcus Dehdarani and Li Liu for tech-
nical assistance, Dr. M.S. Robinson for the cDNA clones of GGA1
and GGA2 and Dr. Cai Zhang for helpful discussions of this work.
This work was in part supported by NIH Grant AG-18933 and the
Pioneer Award from the Alzheimer’s Association to J.T. G.K. is a
Scientist Development Grant Awardee of the American Heart Asso-
ciation. J.T. is holder of the J.G. Puterbaugh Chair in Biomedical
Research at the Oklahoma Medical Research Foundation.
References
[1] Lin, X., Koelsch, G., Wu, S., Downs, D., Dashti, A. and Tang, J.
(2000) Proc. Natl. Acad. Sci. USA 97, 1456^1460.
[2] Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz,
E.A., Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loelo¡,
R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosin-
ski, M.A., Biere, A.L., Curran, E., Burgess, T., Louis, J.C., Col-
lins, F., Treanor, J., Rogers, G. and Citron, M. (1999) Science
286, 735^741.
[3] Hussain, I., Powell, D.J., Howlett, D.R., Chapman, G.A., Gil-
mour, L., Murdock, P.R., Tew, D.G., Meek, T.D., Chapman, C.,
Schneider, K., Ratcli¡e, S.J., Tattersall, D., Testa, T.T., Southan,
C., Ryan, D.M., Simmons, D.L., Walsh, F.S., Dingwall, C. and
Christie, G. (1999) Mol. Cell. Neurosci. 14, 419^427.
[4] Yan, R., Bienkowski, M.J., Shuck, M.E., Miao, H., Tory, M.C.,
Pauley, A.M., Brashier, J.R., Stratman, N.C., Mathews, W.R.,
Buhl, A.E., Carter, D.B., Tomasselli, A.G., Parodi, L.A.,
Heinrikson, R.L. and Gurney, M.E. (1999) Nature 402, 533^
537.
[5] Selko, D. (2001) Physiol. Rev. 81, 741^766.
[6] Bennett, B.D., Denis, P., Haniu, M., Teplow, D.B., Kahn, S.,
Louis, J.C., Citron, M. and Vassar, R. (2000) J. Biol. Chem. 275,
37712^37717.
[7] Capell, A., Steiner, H., Willem, M., Kaiser, H., Meyer, C., Wal-
ter, J., Lammich, S., Multhaup, G. and Haass, C. (2000) J. Biol.
Chem. 275, 30849^30854.
[8] Creemers, J.W., Ines Dominguez, D., Plets, E., Serneels, L., Tay-
lor, N.A., Multhaup, G., Craessaerts, K., Annaert, W. and De
Strooper, B. (2001) J. Biol. Chem. 276, 4211^4217.
Fig. 3. Binding of immobilized GST^VHS domains from GGA1
and GGA2 to memapsin 2 from the lysate of HEK 293 cells trans-
fected for stable expression of memapsin 2. The bound memapsin 2
was visualized by Western blot.
FEBS 26327 19-7-02
X. He et al./FEBS Letters 524 (2002) 183^187186
[9] Huse, J.T., Pijak, D.S., Leslie, G.J., Lee, V.M. and Doms, R.W.
(2000) J. Biol. Chem. 275, 33729^33737.
[10] Mellman, I. (1996) Annu. Rev. Cell Dev. Biol. 12, 575^625.
[11] Rothman, J.E. and Wieland, F.T. (1996) Science 272, 227^
234.
[12] Pastorino, L., Ikin, A.F., Nairn, A.C., Pursnani, A. and Bux-
baum, J.D. (2002) Mol. Cell. Neurosci. 19, 175^185.
[13] Lohi, O., Poussu, A., Mao, Y., Quiocho, F. and Lehto, V. (2002)
FEBS Lett. 513, 19^23.
[14] Puertollano, R., Aguilar, R.C., Gorshkova, I., Crouch, R.J. and
Bonifacino, J.S. (2001) Science 292, 1712^1716.
[15] Zhu, Y., Doray, B., Poussu, A., Lehto, V. and Kornfeld, S.
(2001) Science 292, 1716^1718.
[16] Takatsu, H., Katoh, Y., Shiba, Y. and Nakayama, K. (2001)
J. Biol. Chem. 276, 28541^28545.
[17] Nielsen, M.S., Madsen, P., Christensen, E.I., Nykjaer, A., Glie-
mann, J., Kasper, D., Pohlmann, R. and Petersen, C.M. (2001)
EMBO J. 20, 2180^2190.
[18] Hirst, J., Lui, W.W., Bright, N.A., Totty, N., Seaman, M.N. and
Robinson, M.S. (2000) J. Cell Biol. 149, 67^80.
[19] Kornfeld, S. (1992) Annu. Rev. Biochem. 61, 307^330.
[20] Kirchhausen, T. (2002) Nature Struct. Biol. 9, 241^244.
[21] Lohi, O. and Lehto, V.-P. (1998) FEBS Lett. 440, 255^257.
[22] Shiba, T., Takatsu, H., Nogi, T., Matsugaki, N., Kawasaki, M.,
Igarashi, N., Suzuki, M., Kato, R., Earnest, T., Nakayama, K.
and Wakatsuki, S. (2002) Nature 415, 937^941.
[23] Misra, S., Puertollano, R., Kato, Y., Bonifancino, J.S. and Hur-
ley, J.H. (2002) Nature 415, 933^937.
[24] Turner III, R., Loy, J.A., Nguyen, C., Devasamudram, T.,
Ghosh, A., Koelsch, G. and Tang, J. (2002) Biochemistry 41,
8742^8746.
[25] Chyung, A.S.C., Greenberg, B.D., Cook, D.G., Doms, R.W. and
Lee, V.M. (1997) J. Cell Biol. 138, 671^680.
[26] Xia, W., Zhang, J., Ostaszewski, B.L., Kimberly, W.T., Seubert,
P., Koo, E.H., Shen, J. and Selkoe, D.J. (1998) Biochemistry 37,
16465^16471.
FEBS 26327 19-7-02
X. He et al./FEBS Letters 524 (2002) 183^187 187
